第一届国际三阴性乳腺癌会议报告。
First international TNBC conference meeting report.
机构信息
Department of Biology, Georgia State University, Atlanta, GA, USA.
Novazoi Theranostics, Rolling Hills Estates, CA, USA.
出版信息
Breast Cancer Res Treat. 2018 Jun;169(3):407-412. doi: 10.1007/s10549-018-4692-3. Epub 2018 Feb 8.
Abstract
Recently, Georgia State University's Centennial Hall was the premier location for the 2017 International Conference on Triple Negative Breast Cancer (TNBC): Illuminating Actionable Biology, which was held from Sept. 18 to 20, 2017, in Atlanta, USA. The conference featured a stellar line-up of domestic and international speakers and diverse participants including TNBC survivors, luminaries in breast cancer research, medical students and fellows, clinicians, translational researchers, epidemiologists, biostatisticians, bioinformaticians, and representatives from the industry. This report distills the burning questions that spiked the event and summarizes key themes, findings, unique opportunities and future directions that emerged from this confluence of thought leaders.
摘要
最近，佐治亚州立大学的百年纪念堂成为了 2017 年三阴性乳腺癌（TNBC）国际会议的首选地点：探索可操作的生物学，该会议于 2017 年 9 月 18 日至 20 日在美国亚特兰大举行。会议的演讲者阵容强大，包括国内外的演讲者和来自 TNBC 幸存者、乳腺癌研究领域的杰出人士、医学生和研究员、临床医生、转化研究人员、流行病学家、生物统计学家、生物信息学家以及行业代表等多样化的参与者。本报告提炼了引发此次活动的热点问题，并总结了此次思想领袖云集所产生的关键主题、发现、独特机会和未来方向。
相似文献
1
First international TNBC conference meeting report.第一届国际三阴性乳腺癌会议报告。
Breast Cancer Res Treat. 2018 Jun;169(3):407-412. doi: 10.1007/s10549-018-4692-3. Epub 2018 Feb 8.
2
Role of Immunotherapy in Triple-Negative Breast Cancer.免疫疗法在三阴性乳腺癌中的作用。
J Natl Compr Canc Netw. 2020 Apr;18(4):479-489. doi: 10.6004/jnccn.2020.7554.
3
Immune microenvironment of triple-negative breast cancer in African-American and Caucasian women.非裔美国人和白种人女性中三阴性乳腺癌的免疫微环境。
Breast Cancer Res Treat. 2019 May;175(1):247-259. doi: 10.1007/s10549-019-05156-5. Epub 2019 Feb 6.
4
PD-L1 testing based on the SP142 antibody in metastatic triple-negative breast cancer: summary of an expert round-table discussion.基于 SP142 抗体的 PD-L1 检测在转移性三阴性乳腺癌中的应用：专家圆桌讨论综述。
Future Oncol. 2021 Apr;17(10):1209-1218. doi: 10.2217/fon-2020-1100. Epub 2020 Dec 8.
5
The impact of distinct triple-negative breast cancer subtypes on misdiagnosis and diagnostic delay.不同三阴性乳腺癌亚型对误诊和诊断延迟的影响。
Breast Cancer Res Treat. 2019 Aug;177(1):67-75. doi: 10.1007/s10549-019-05298-6. Epub 2019 Jun 1.
6
Emerging CAR-T Cell Therapy for the Treatment of Triple-Negative Breast Cancer.新兴的嵌合抗原受体 T 细胞疗法治疗三阴性乳腺癌。
Mol Cancer Ther. 2020 Dec;19(12):2409-2421. doi: 10.1158/1535-7163.MCT-20-0385. Epub 2020 Oct 21.
7
Recent Progress in Triple Negative Breast Cancer Research.三阴性乳腺癌研究的最新进展
Asian Pac J Cancer Prev. 2016;17(4):1595-608. doi: 10.7314/apjcp.2016.17.4.1595.
8
Panoptic Overview of Triple-Negative Breast Cancer in Nigeria: Current Challenges and Promising Global Initiatives.尼日利亚三阴性乳腺癌全景概述：当前挑战与充满希望的全球倡议
J Glob Oncol. 2018 Jul;4:1-20. doi: 10.1200/JGO.17.00116.
9
Long non-coding RNAs: implications in targeted diagnoses, prognosis, and improved therapeutic strategies in human non- and triple-negative breast cancer.长非编码 RNA：在人类非三阴性和三阴性乳腺癌的靶向诊断、预后和改进治疗策略中的意义。
Clin Epigenetics. 2018 Jun 27;10:88. doi: 10.1186/s13148-018-0514-z. eCollection 2018.
10
Tumor immune microenvironment and genomic evolution in a patient with metastatic triple negative breast cancer and a complete response to atezolizumab.转移性三阴性乳腺癌患者的肿瘤免疫微环境和基因组进化以及对阿替利珠单抗的完全应答。
J Immunother Cancer. 2019 Oct 23;7(1):274. doi: 10.1186/s40425-019-0740-8.
引用本文的文献
1
Application and Progress of Antibody-Drug Conjugates (ADCs) in the Treatment of Metastatic Triple-Negative Breast Cancer.抗体药物偶联物（ADCs）在转移性三阴性乳腺癌治疗中的应用与进展
Oncol Ther. 2025 Sep 15. doi: 10.1007/s40487-025-00379-7.
2
RBM15 enhances paclitaxel resistance in triple-negative breast cancer by targeting mA methylation of TNFSF9 and inducing polarization of tumor-associated macrophages to M2 phenotype.RBM15通过靶向TNFSF9的mA甲基化并诱导肿瘤相关巨噬细胞极化为M2表型来增强三阴性乳腺癌对紫杉醇的耐药性。
Hereditas. 2025 Aug 19;162(1):167. doi: 10.1186/s41065-025-00534-0.
3
DLAT promotes triple-negative breast cancer progression via YAP1 activation.DLAT 通过激活 YAP1 促进三阴性乳腺癌的进展。
Cancer Biol Ther. 2024 Dec 31;25(1):2421578. doi: 10.1080/15384047.2024.2421578. Epub 2024 Oct 26.
4
Identifying High-Risk Triple-Negative Breast Cancer Patients by Molecular Subtyping.通过分子分型识别高危三阴性乳腺癌患者
Breast Care (Basel). 2021 Dec;16(6):637-647. doi: 10.1159/000519255. Epub 2021 Oct 19.
5
LncRNA-HAGLR motivates triple negative breast cancer progression by regulation of WNT2 via sponging miR-335-3p.长链非编码 RNA-HAGLR 通过海绵吸附 miR-335-3p 调控 WNT2 促进三阴性乳腺癌进展。
Aging (Albany NY). 2021 Aug 10;13(15):19306-19316. doi: 10.18632/aging.203272.
6
Targets and Mechanism Used by Cinnamaldehyde, the Main Active Ingredient in Cinnamon, in the Treatment of Breast Cancer.肉桂中的主要活性成分肉桂醛用于治疗乳腺癌的靶点及机制
Front Pharmacol. 2020 Dec 9;11:582719. doi: 10.3389/fphar.2020.582719. eCollection 2020.
7
Calcitriol Inhibits the Proliferation of Triple-Negative Breast Cancer Cells through a Mechanism Involving the Proinflammatory Cytokines IL-1 and TNF-.骨化三醇通过涉及促炎细胞因子 IL-1 和 TNF-的机制抑制三阴性乳腺癌细胞的增殖。
J Immunol Res. 2019 Apr 10;2019:6384278. doi: 10.1155/2019/6384278. eCollection 2019.
8
The Novel Mnk1/2 Degrader and Apoptosis Inducer VNLG-152 Potently Inhibits TNBC Tumor Growth and Metastasis.新型Mnk1/2降解剂和凋亡诱导剂VNLG-152有效抑制三阴性乳腺癌肿瘤生长和转移。
Cancers (Basel). 2019 Mar 3;11(3):299. doi: 10.3390/cancers11030299.
9
Therapeutic impact of Nintedanib with paclitaxel and/or a PD-L1 antibody in preclinical models of orthotopic primary or metastatic triple negative breast cancer.尼达尼布联合紫杉醇和/或 PD-L1 抗体在原位原发性或转移性三阴性乳腺癌的临床前模型中的治疗作用。
J Exp Clin Cancer Res. 2019 Jan 11;38(1):16. doi: 10.1186/s13046-018-0999-5.
本文引用的文献
1
Androgen Receptor Immunohistochemistry as a Companion Diagnostic Approach to Predict Clinical Response to Enzalutamide in Triple-Negative Breast Cancer.雄激素受体免疫组化作为预测三阴性乳腺癌对恩杂鲁胺临床反应的伴随诊断方法
JCO Precis Oncol. 2017 Nov;1:1-19. doi: 10.1200/PO.17.00075.
2
Triple negative breast cancer: Emerging therapeutic modalities and novel combination therapies.三阴性乳腺癌：新兴的治疗方式和新型联合疗法。
Cancer Treat Rev. 2018 Jan;62:110-122. doi: 10.1016/j.ctrv.2017.11.003. Epub 2017 Nov 13.
3
Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States.美国可改变的潜在风险因素导致的癌症病例和死亡人数及比例。
CA Cancer J Clin. 2018 Jan;68(1):31-54. doi: 10.3322/caac.21440. Epub 2017 Nov 21.
4
Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study.avelumab，一种抗 PD-L1 抗体，用于局部晚期或转移性乳腺癌患者：JAVELIN 固体肿瘤研究 1b 期。
Breast Cancer Res Treat. 2018 Feb;167(3):671-686. doi: 10.1007/s10549-017-4537-5. Epub 2017 Oct 23.
5
Perspectives in immunotherapy: meeting report from the "Immunotherapy Bridge", Napoli, November 30th 2016.免疫疗法透视：“免疫疗法桥梁”会议报告，2016 年 11 月 30 日，那不勒斯。
J Transl Med. 2017 Oct 11;15(1):205. doi: 10.1186/s12967-017-1309-2.
6
Biology and Etiology of Young-Onset Breast Cancers among Premenopausal African American Women: Results from the AMBER Consortium.绝经前非裔美国女性中早发性乳腺癌的生物学和病因学：来自 AMBER 联盟的结果。
Cancer Epidemiol Biomarkers Prev. 2017 Dec;26(12):1722-1729. doi: 10.1158/1055-9965.EPI-17-0450. Epub 2017 Sep 13.
7
FOXA1 hypermethylation: link between parity and ER-negative breast cancer in African American women?FOXA1 甲基化：非裔美国女性生育次数与 ER 阴性乳腺癌之间的联系？
Breast Cancer Res Treat. 2017 Nov;166(2):559-568. doi: 10.1007/s10549-017-4418-y. Epub 2017 Jul 29.
8
Triple-negative breast cancer: the importance of molecular and histologic subtyping, and recognition of low-grade variants.三阴性乳腺癌：分子和组织学亚型分类的重要性以及低级别变异型的识别
NPJ Breast Cancer. 2016 Nov 16;2:16036. doi: 10.1038/npjbcancer.2016.36. eCollection 2016.
9
Single-Cell Dynamics Determines Response to CDK4/6 Inhibition in Triple-Negative Breast Cancer.单细胞动力学决定三阴性乳腺癌对 CDK4/6 抑制的反应。
Clin Cancer Res. 2017 Sep 15;23(18):5561-5572. doi: 10.1158/1078-0432.CCR-17-0369. Epub 2017 Jun 12.
10
Health Disparities and Triple-Negative Breast Cancer in African American Women: A Review.非裔美国女性的健康差异与三阴性乳腺癌：综述。
JAMA Surg. 2017 May 1;152(5):485-493. doi: 10.1001/jamasurg.2017.0005.
Zotero 插件